Association of TP53 rs1042522 C>G Polymorphism with Glioma Risk in Chinese Children

Table 2

Stratification analysis between TP53 rs1042522 C>G polymorphism and glioma risk.

Variables	rs1042522 (cases/controls)		Crude OR		Adjusted OR^a	^a
	CC	CG/GG	(95% CI)		(95% CI)
Age, month
<60	29/32	56/87	0.71 (0.39-1.30)	0.267	0.71 (0.39-1.30)	0.269
≥60	25/33	61/76	1.06 (0.57-1.97)	0.855	1.08 (0.58-2.01)	0.814
Gender
Female	27/27	54/66	0.82 (0.43-1.56)	0.541	0.81 (0.42-1.56)	0.534
Male	27/38	63/97	0.91 (0.51-1.64)	0.764	0.93 (0.52-1.68)	0.815
Subtypes
Astrocytic tumors	39/65	86/163	0.88 (0.55-1.41)	0.596	0.91 (0.56-1.48)	0.709
Ependymoma	9/65	16/163	0.71 (0.30-1.69)	0.436	0.69 (0.29-1.65)	0.405
Neuronal and mixed	3/65	11/163	1.46 (0.40-5.41)	0.569	1.37 (0.37-5.14)	0.638
Embryonal tumors	3/65	4/163	0.53 (0.12-2.44)	0.417	0.67 (0.12-3.69)	0.647
Clinical stages
I	31/65	72/163	0.93 (0.56-1.54)	0.768	0.92 (0.55-1.55)	0.764
II	9/65	19/163	0.84 (0.36-1.96)	0.689	0.84 (0.36-1.96)	0.684
III	6/65	9/163	0.60 (0.21-1.75)	0.348	0.57 (0.19-1.67)	0.302
IV	8/65	17/163	0.85 (0.35-2.06)	0.715	1.21 (0.45-3.21)	0.706
I+II	40/65	91/163	0.91 (0.57-1.45)	0.685	0.91 (0.56-1.46)	0.684
III+IV	14/65	26/163	0.74 (0.36-1.51)	0.407	0.83 (0.40-1.73)	0.623

OR: odds ratio; CI: confidence interval. ^aAdjusted for age and gender: omitting the corresponding stratify factor.